Practical use of apixaban in the prevention of venous thromboembolism after total knee or hip replacement

Drugs of Today

Volumn 48, Issue 4, 2012, Pages 249-258

  Lassen, Michael Rud ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Anticoagulant; Apixaban; Total hip replacement; Total knee replacement; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; CARBAMAZEPINE; ENOXAPARIN; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PHENYTOIN; POSACONAZOLE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIFAMPICIN; VORICONAZOLE;

AGE; ANESTHESIA; BLEEDING; BLOOD TRANSFUSION; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MORTALITY; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; UPPER GASTROINTESTINAL BLEEDING; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BLOOD COAGULATION; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; PATIENT SELECTION; PYRAZOLES; PYRIDONES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84860769793     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.4.1738052     Document Type: Review

References (48)

1. Geerts, W.H., Bergqvist, D., Pineo, G.F., Heit, J.A., Samama, C.M., Lassen, M.R., Colwell, C.W.; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(6, Suppl.): 381S-453S. (Pubitemid 351894916)
2. White, R.H., Romano, P.S., Zhou, H., Rodrigo, J., Bargar, W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998, 158(14): 1525-31. (Pubitemid 28340985)
3. Bauer, K.A. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost 2011, 9(Suppl. 1): 12-9.
4. Warwick, D., Friedman, R.J., Agnelli, G., Gil-Garay, E., Johnson, K., FitzGerald, G., Turibio, F.M. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 2007, 89(6): 799-807. (Pubitemid 47180202)
5. Borris, L.C. Barriers to the optimal use of anticoagulants after orthopaedic surgery. Arch Orthop Trauma Surg 2009, 129(11): 1441-5.
6. Lassen, M.R., Raskob, G.E., Gallus, A., Pineo, G., Chen, D., Hornick, P.; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010, 375(9717): 807-15.
7. Lassen, M.R., Gallus, A., Raskob, G.E., Pineo, G., Chen, D., Ramirez, L.M., for the ADVANCE-3 investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010, 363(26): 2487-98.
8. Eliquis. Summary of product characteristics. http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR---Product-Information/human/002148/WC500107728. pdf/ Assessed: October 2011.
9. Lassen, M.R., Raskob, G.E., Gallus, A., Pineo, G., Chen, D., Portman, R.J. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009, 361(6): 594-604; erratum N Engl J Med 2009, 361(18): 1814.
10. Ginzburg, E., Dujardin, F. Physicians' perceptions of the definition of major bleeding in major orthopedic surgery: results of an international survey. J Thromb Thrombolysis 2011, 31(2): 188-95.
11. Saleh, K., Olson, M., Resig, S. et al. Predictors of wound infection in hip and knee joint replacement: results from a 20 year surveillance program. J Orthop Res 2002, 20(3): 506-15. (Pubitemid 34464075)
12. Schulman, S., Angerås, U., Bergqvist, D., Eriksson, B., Lassen, M.R., Fisher, W.; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010, 8(1): 202-4.
13. Rosencher, N., Zufferey, P., Samama, C.M. Definition of major bleeding in surgery: an anesthesiologist's point of view: a rebuttal. J Thromb Haemost 2010, 8(6): 1442-3.
14. Vera-Llonch, M., Hagiwara, M., Oster, G. Clinical and economic consequences of bleeding following major orthopedic surgery. Thromb Res 2006, 117(5): 569-77. (Pubitemid 43326144)
15. Eikelboom, J.W., Quinlan, D.J., O'Donnell, M. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 2009, 120(20):2006-11.
16. Guijarro, R., Montes, J., San Román, C., Arcelus, J.I., Barillari, G., Granero, X., Monreal, M. Venous thromboembolism and bleeding after total knee and hip arthroplasty. Findings from the Spanish National Discharge Database. Thromb Haemost 2011, 105(4): 610-5.
17. Borris, L.C. Emerging antithrombotic agents for thromboprophylaxis, clinical potential and patient considerations. J Blood Med 2010, 1: 123-30.
18. Turpie, A.G., Bauer, K.A., Eriksson, B.I., Lassen, M.R. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 2003, 90(2): 364-6. (Pubitemid 36992515)
19. Gouin-Thibault, I., Pautas, E., Siguret, V. Safety profile of different low-molecular weight heparins used at therapeutic dose. Drug Saf 2005, 28(4): 333-49. (Pubitemid 40545768)
20. Randelli, F., Biggi, F., Della Rocca, G. et al. Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgery. J Orthop Traumatol 2011, 12(1): 69-76.
21. Gerlach, A.T., Pickworth, K.K., Seth, S.K., Tanna, S.B., Barnes, J.F. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000, 20(7): 771-5. (Pubitemid 30457356)
22. Limdi, N.A., Limdi, M.A., Cavallari, L. et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis 2010, 56(5): 823-31.
23. Mahe, I., Gouin-Thibault, I., Drouet, L. et al. Elderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level. Drugs Aging 2007, 24(1): 63-71. (Pubitemid 46148082)
24. Dahl, O.E. Orthopaedic surgery as a model for drug development in thrombosis. Drugs 2004, 64(Suppl. 1): 17-25. (Pubitemid 39280366)
25. The European Agency for the Evaluation of Medicinal Products, Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operativevenous thromboembolic risk. Available at: http://www.emea.europa.eu/pdfs/human/ewp/ 70798en-fin.pdf. Assessed: September 2011.
26. Strebel, N., Prins, M., Agnelli, G., Büller, H.R. Preoperative or postoperative start of prophylaxis for venous thromboemboism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 2002, 162(13): 1451-6. (Pubitemid 34747477)
27. Raskob, G.E., Hirsh, J. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest 2003, 124(6, Suppl.): 379S-385S. (Pubitemid 38005465)
28. Lassen, M.R., Davidson, B.L., Gallus, A., Pineo, G., Ansell, J., Deitchman, D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007, 5(12): 2368-75. (Pubitemid 350154345)
29. Leil, T.A., Feng, Y., Zhang, L., Paccaly, A., Mohan, P., Pfister, M. Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin Pharmacol Ther 2010, 88(3): 375-82.
30. rd Cong Int Soc Thromb Haemostas (July 23-28, Kyoto) 2011] 2011, 9 (Suppl. 2): Abst. P-WE-159.
31. Dahl, O.E., Ogren, M., Agnelli, G. et al. Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty. Pathophysiol Haemost Thromb 2006, 35(6): 428-34. (Pubitemid 46895716)
32. Fransen, M., Anderson, C., Douglas, J. et al. Safety and efficacy of routine postoperative ibuprofen for pain and disability related to ectopic bone formation after hip replacement surgery (HIPAID): randomised controlled trial. BMJ 2006, 333(7567): 519.
33. Sharma, S. Upper gastrointestinal bleeding after hip and knee arthroplasty. Orthopedics 2006, 29(3): 255-7. (Pubitemid 43379851)
34. Dahl, O.E., Quinlan, D.J., Bergqvist, D., Eikelboom, J.W. A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. J Thromb Haemost 2010, 8(9): 1966-75.
35. Schulman, S., Kearon, C.; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005, 3(4): 692-4. (Pubitemid 41647882)
36. Jensen, C.D., Steval, A., Partington, P.F., Reed, M.R., Muller, S.D. Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study. J Bone Joint Surg Br 2011, 93(1): 91-5.
37. Gogarten, W., Vandermeulen, E., Van Aken, H., Kozek, S., Llau, J.V., Samama, C.M. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol 2010, 27(12): 999-1015.
38. Rosencher, N., Bonnet, M.P., Sessler, D.I. Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies. Anaesthesia 2007, 62(11): 1154-60. (Pubitemid 47556416)
39. Huo M.H. New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: are they really better? Thromb Haemost 2011, 106(1): 45-57.
40. Barrett, Y.C., Wang, Z., Frost, C., Shenker, A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010, 104(6): 1263-71.
41. Cohen, A.T., Tapson, V.F., Bergmann, J.-F. et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008, 371(9610): 387-94. (Pubitemid 351173321)
42. Kakkar, A.K., Cohen, A.T., Tapson, V.F. et al. Venous thromboembolism risk and prophylaxis in the acute care hospital setting (ENDORSE survey): findings in surgical patients. Ann Surg 2010, 251(2): 330-8.
43. Fareed, J., Hull, R. Apixaban to prevent venous thromboembolism after knee replacement. Lancet 2010, 375(9717): 779-80.
44. Grabowska-Gawe, A., Porzych, K., Piskunowicz, G. Risk factors and frequency of postoperative nausea and vomiting in patients operated under general anesthesia. Przegl Lek 2006, 63(2): 72-6.
45. Bellamy, L., Rosencher, N., Eriksson, B. Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate. Patient Prefer Adherence 2009, 3: 173-7.
46. Haynes, R.B., Ackloo, E., Sahota, N., McDonald, H.P., Yao, X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008, (2): CD000011.
47. Claxton, A.J., Cramer, J., Pierce, C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23(8): 1296-310. (Pubitemid 32804122)
48. Comté, L., Vrijens, B., Tousset, E., Gérard, P., Urquhart, J. Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J Pharmacokinet Pharmacodyn 2007, 34(4): 549-58. (Pubitemid 47038128)